

# ARS-1620

**Catalog No: tcsc0035119**



## Available Sizes

---

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg

**Size:** 50mg

**Size:** 100mg

**Size:** 200mg



## Specifications

---

**CAS No:**

1698055-85-4

**Formula:**

$C_{21}H_{17}ClF_2N_4O_2$

**Pathway:**

GPCR/G Protein

**Target:**

Ras

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 53$  mg/mL (123.02 mM)

**Observed Molecular Weight:**

430.84


## Product Description

ARS-1620 is an atropisomeric selective **KRAS<sup>G12C</sup>** inhibitor with desirable pharmacokinetics.

IC<sub>50</sub> & Target: KRAS<sup>G12C</sup>[1]

**In Vitro:** ARS-1620 is an atropisomeric selective KRAS<sup>G12C</sup> inhibitor with desirable pharmacokinetics. ARS-1620 exhibits complete growth suppression of p.G12C cell lines (IC<sub>50</sub>=150 nM) with relatively benign effects on control cell lines. It is found that ARS-1620 significantly reduces expression of the gene set in p.G12C mutant cells in a time-dependent manner but not in the p.G12S mutant cells. Following a 5-day treatment period, only a minority of G12C mutant cell lines are sensitive to ARS-1620 under monolayer culture conditions, whereas in 3D-spheroid conditions, ARS-1620 elicits a robust response (p=0.0140)<sup>[1]</sup>.

**In Vivo:** Following a single oral dose or 5 consecutive daily doses, ARS-1620 yields average peak tumor concentrations of 1.5 μM (50 mg/kg) and 5.5 μM (200 mg/kg), respectively, that enables significant KRAS<sup>G12C</sup> target occupancy (>=70% G12C-TE at 200 mg/kg) for >24 hr. In MIAPaCa2 xenografts (p.G12C), ARS-1620 significantly inhibits tumor growth (p



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!